Lloyd Klickstein
Founder at Versanis Bio, Inc.
Profile
Lloyd Klickstein is the founder.
He founded Versanis Bio, Inc. in 2021 and currently holds the title of President & Chief Scientific Officer.
Dr. Klickstein also held former positions at Blade Therapeutics, Inc. as a Director from 2019 to 2023, at Novartis Institutes for Biomedical Research, Inc. as the Head-Translational Medicine, at resTORbio, Inc. as the Chief Scientific Officer from 2019 to 2020, and at Adicet Bio, Inc. as the Chief Innovation Officer from 2019 to 2021.
Dr. Klickstein's education includes a doctorate from Harvard University and an undergraduate degree from Tufts University.
Lloyd Klickstein active positions
| Companies | Position | Start |
|---|---|---|
Versanis Bio, Inc.
 Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Founder | 01/02/2021 |
Former positions of Lloyd Klickstein
| Companies | Position | End |
|---|---|---|
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Director/Board Member | 01/02/2023 |
| ADICET BIO, INC. | Corporate Officer/Principal | 19/02/2021 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| ADICET BIO, INC. | Chief Tech/Sci/R&D Officer | 15/09/2020 |
Training of Lloyd Klickstein
| Tufts University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ADICET BIO, INC. | Health Technology |
| Private companies | 4 |
|---|---|
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Commercial Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Health Technology |
- Stock Market
- Insiders
- Lloyd Klickstein
